Viewing Study NCT01603251


Ignite Creation Date: 2025-12-24 @ 11:49 PM
Ignite Modification Date: 2025-12-31 @ 5:46 AM
Study NCT ID: NCT01603251
Status: COMPLETED
Last Update Posted: 2013-04-18
First Post: 2012-05-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Trial of Artemether-Lumefantrine Alone and in Combination With Ivermectin to Reduce Post-Treatment Malaria Transmission
Sponsor: London School of Hygiene and Tropical Medicine
Organization:

Study Overview

Official Title: A Double Blind Randomized Controlled Trial of Artemether-Lumefantrine Alone and in Combination With Ivermectin to Reduce Post-Treatment Malaria Transmission
Status: COMPLETED
Status Verified Date: 2013-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: ACTIVE
Brief Summary: The purpose of this study is to determine the safety and impact of ivermectin, administered as single or repeated dose, in combination with artemether-lumefantrine in reducing the proportion of mosquitoes that survive and become infected after feeding on a blood meal from a malaria-infected individual.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: